Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Nortriptyline
Drug ID BADD_D01588
Description Nortriptyline hydrochloride, the active metabolite of [amitriptyline], is a tricyclic antidepressant (TCA).[L11878] It is used in the treatment of major depression and is also used off-label for chronic pain and other conditions.[L11881]
Indications and Usage Nortriptyline is indicated for the relief of the symptoms of major depressive disorder (MDD).[L11878] Some off-label uses for this drug include treatment of chronic pain, myofascial pain, neuralgia, and irritable bowel syndrome.[A191083,L11878]
Marketing Status approved
ATC Code N06AA10
DrugBank ID DB00540
KEGG ID D08288
MeSH ID D009661
PubChem ID 4543
TTD Drug ID D04WFD
NDC Product Code Not Available
UNII BL03SY4LXB
Synonyms Nortriptyline | Desitriptyline | Desmethylamitriptylin | Allegron | Apo-Nortriptyline | Apo Nortriptyline | Aventyl | Gen-Nortriptyline | Gen Nortriptyline | Paxtibi | Nortrilen | Nortriptyline Hydrochloride | Hydrochloride, Nortriptyline | Novo-Nortriptyline | Novo Nortriptyline | Nu-Nortriptyline | Nu Nortriptyline | Pamelor | PMS-Nortriptyline | PMS Nortriptyline | ratio-Nortriptyline | ratio Nortriptyline | Norfenazin
Chemical Information
Molecular Formula C19H21N
CAS Registry Number 72-69-5
SMILES CNCCC=C1C2=CC=CC=C2CCC3=CC=CC=C31
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Seizure17.12.03.0010.000237%
Sensory loss17.02.07.007--Not Available
Shock24.06.02.002--Not Available
Somnolence19.02.05.003; 17.02.04.006--
Stomatitis07.05.06.005--
Suicidal ideation19.12.01.0030.000119%
Swollen tongue10.01.05.015; 07.14.02.003; 23.04.01.014--Not Available
Syncope02.11.04.015; 24.06.02.012; 17.02.04.0080.000119%
Tachycardia02.03.02.0070.000119%Not Available
Tension19.06.02.005--Not Available
Testicular swelling21.13.01.003--Not Available
Throat irritation22.12.03.029; 07.05.05.0370.000404%Not Available
Thrombocytopenia01.08.01.002--Not Available
Tinnitus17.04.07.004; 04.04.01.002--
Tongue discolouration07.14.02.006--Not Available
Tongue disorder07.14.01.002--Not Available
Tongue oedema23.04.01.009; 10.01.05.008; 07.14.02.007--Not Available
Torsade de pointes02.03.04.005--Not Available
Tremor17.01.06.002--
Urinary retention20.02.02.011--
Urticaria23.04.02.001; 10.01.06.001--
Vascular purpura24.07.06.011; 23.06.01.008; 01.01.04.007--Not Available
Ventricular fibrillation02.03.04.008--
Ventricular tachycardia02.03.04.010--
Vertigo17.02.12.002; 04.04.01.003--
Vision blurred17.17.01.010; 06.02.06.007--
Visual impairment06.02.10.013--Not Available
Vomiting07.01.07.003--
Weight decreased13.15.01.005--
Weight increased13.15.01.006--
The 5th Page    First    Pre   5 6    Next   Last    Total 6 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene